ArrayPatch
Private Company
Funding information not available
Overview
ArrayPatch is a clinical-stage, privately-held biotech company developing a novel, polymer-free dissolvable microneedle patch platform called DerMap™. The company is pursuing a fast-track 505(b)(2) regulatory pathway for its lead program, ITZ-DerMap™, targeting the multi-billion dollar nail fungus market, with an initial focus on high-risk diabetic patients. Backed by prestigious awards and a €3M seed round, ArrayPatch is leveraging its platform technology to build a pipeline in dermatology and beyond, including skin cancer and migraine. The leadership team combines scientific, clinical, and commercial expertise to advance its patient-centric, pain-free drug delivery solutions.
Technology Platform
DerMap™: A polymer-free, dissolvable microneedle patch platform where each microneedle is composed entirely of the drug substance, enabling high-loading, pain-free, targeted transdermal drug delivery.
Opportunities
Risk Factors
Competitive Landscape
ArrayPatch competes in the growing transdermal microneedle patch sector against both large pharma (e.g., Vaxxas, Micron Biomedical) and specialty drug delivery companies. Its polymer-free, high-drug-loading technology is a key differentiator, but it must demonstrate clinical superiority or convenience advantages to capture market share.